Considering the combination was effective in WSU-DLCL2 cells, a Myc, BCL-2/6 double hit model, these results provide strong indication that the combinations may be viable therapeutic options regardless of the mutational status of Myc and BCL-2/6 in therapy resistant NHL. This evidence concerns the gene BCL2 and non-Hodgkin lymphoma.